期刊文献+

“赵氏脱疽方”干预AGEs及糖尿病足相关因子的研究 被引量:2

The Research of "Zhao's Prescription" Intervention-AGEs and Related Factors of Diabetic Foot
下载PDF
导出
摘要 目的:探讨"赵氏脱疽方"治疗糖尿病足,干预血脂、糖基化终末产物(AGEs)及相关因子的作用。方法:将符合纳入标准的糖尿病足患者39例随机分成3组,各组在给予糖尿病常规治疗基础上,给予纯中药组(13例)口服赵氏脱疽汤,并用赵氏脱疽膏外敷;给予中西药结合组(12例)口服赵氏脱疽汤,并用依沙吖啶外敷;给予纯西药对照组(14例)口服已酮可可碱,并用依沙吖啶外敷。观察各组治疗前后糖化血红蛋白、AGEs等。结果:3组治疗前后有明显变化,各组疗效比较,纯中药组疗效优于中西药结合组,纯中药组和中西药结合组疗效均明显优于西药对照组。结论:中医药治疗糖尿病足坏疽有其独特优势,"赵氏脱疽方"对于AGE及相关因子均有不同程度的改善,同时配合中药外治糖尿病足坏疽有明显优势。 Objective:It is to discuss "Zhao's Prescription"intervention-AGEs and related factors to improve the treatment of diabetic foot.Methods: 39 cases of diabetic foot patients were divided into three groups,and each group were given conventional treatment of diabetes.Chinese medicine group(13 cases) is given oral Zhao's Prescription soup,and with Zhao's Prescription cream;Integrative medicine group(12 cases) is given Zhao's Prescription soup,and use topical ethacridine;Comparison group(14 cases),is given administration of pentoxifylline and topical use ethacridine.we observed the index change of glycosylated hemoglobin,lipids and Advanced glycation end products(AGEs) and so on before and after treatment.Results: There are significant changes before and after treatment in the three groups,.Chinese medicine group is superior to the Integrative medicine group,Chinese medicine group and the Integrative medicine group was significantly better than comparison group.Conclusion:TCM treatment of diabetic foot gangrene has its unique advantages.The results show that "Zhao's Prescription soup" for AGE,blood sugar,blood lipid get improvement in different degrees,and using external traditional Chinese medicine has obvious advantages on curing diabetic foot gangrene
出处 《中国中医基础医学杂志》 CAS CSCD 北大核心 2012年第1期69-70,74,共3页 JOURNAL OF BASIC CHINESE MEDICINE
基金 人事部国家中医药管理局资助项目(2005LHR01) 中国博士后基金资助项目(2008年104号)
关键词 糖尿病足 赵氏脱疽方 血糖 血脂 AGES Diabetic Foot " Zhao's Prescription" Blood sugar Blood lipid AGEs
  • 相关文献

参考文献5

二级参考文献34

  • 1李光伟.糖尿病患者脂类代谢紊乱的临床及其治疗[J].中国糖尿病杂志,1995,3(2):116-118. 被引量:43
  • 2李仕明.糖尿病足(肢端坏疽)的诊断与治疗[J].中级医刊,1997,32(4):10-14. 被引量:50
  • 3Lorenzi M.Glucose toxicity in the vascular complications of diabetes:the cellular perspective[J].Diabetes Metab Rev,1999,8(2):85-103.
  • 4Pamplona R,Bellmunt MJ,Portero M,et al.Mechanisms of glycation in atherogenesis[J].Med Hypotheses,2005,40(3):174-181.
  • 5Shinohara M,Thornalley PJ,Giardino I,et al.Overexpression of glyoxalase-Ⅰ in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis[J].J Clin Invest,2008,101:1142-1147.
  • 6Sugaya K,Fukagawa T,Matsumoto K,et al.Three genes in the human MHC class Ⅲ region near the junction with the class Ⅱ gene for receptor of advanced glycosylation end products,PBX2 homeobox gene and a notch homolog,human counterpart of mouse mammary tumor gene int-3[J].Genomics,2004,23:408-419.
  • 7Yan SF,Ramasamy R,Naka Y,et al.Glycation,inflammation,and RAGE:a scaffold for the macrovascular complications of diabetes and beyond[J].Circ Res,2007,93:1159-1169.
  • 8Kislinger T,Fu C,Huber B,et al.N -(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression[J].J Biol Chem,1999,274:31740-31749.
  • 9Schmidt AM,Yan SD,Yan SF,et al.The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses[J].J Clin Invest,2007,108:949-955.
  • 10Makino H,Shikata K,Kushiro M,et al.Roles of advanced glycation end-products in the progression of diabetic nephropathy[J].Nephrol Dial Transplant,2006,11(Suppl 5):76-80.

共引文献37

同被引文献35

引证文献2

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部